Skip Navigation LinksHome > Published Ahead-of-Print > Systemic Therapy in Advanced Cutaneous Squamous Cell Carcino...
American Journal of Clinical Oncology:
doi: 10.1097/COC.0000000000000088
Original Article: PDF Only

Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC): The Roswell Park Experience and a Review of the Literature.

Jarkowski, Anthony III PharmD, BCOP; Hare, Ryan PharmD; Loud, Peter MD; Skitzki, Joseph J. MD; Kane, John M. III MD; May, Kilian S. MD; Zeitouni, Nathalie C. MD; Nestico, Jill RN, MSN; Vona, Karen L. RN, MSN; Groman, Adrienne MS; Khushalani, Nikhil I. MD

Published Ahead-of-Print
Collapse Box

Abstract

Objectives: Treatment of locally advanced unresectable or metastatic cutaneous squamous cell carcinoma (mCSCC) is suboptimal with a paucity of robust data on systemic therapy. This retrospective study aimed to evaluate the efficacy and outcomes of patients with locally advanced unresectable or mCSCC treated with systemic therapy.

Methods: Records of patients with CSCC treated with systemic therapy from January 2001 to January 2011 were reviewed. Response was assessed using WHO criteria. Descriptive results were assessed using Wilcoxon rank-sum test for ordinal responses and Pearson [chi]2 test for categorical responses. Survival was calculated by the Kaplan-Meier method.

Results: Of 28 patients identified, 25 patients (M:F=18:7), median age 66 years (range, 39 to 85 y), had the required data for final analysis. Partial response was 44% and stable disease (SD) was 24%. The median progression-free survival (PFS) and overall survival (OS) were 5.5 months (2.3, 13.2) and 10.9 months (5.3, 21.3) respectively; 3-year OS was 22%. Patients with WHO response had improved PFS (20.8 mo; 4.4, NR) and OS (37.5 mo; 10.3, NR) compared with patients with SD/PD (PFS 2.7 mo; OS 5.9 mo). Use of platinum-based therapy significantly improved PFS and OS, whereas taxanes and cetuximab had no impact in this small cohort. There was no difference in PFS or OS with multiagent versus single-agent therapy.

Conclusions: Platinum-based therapy remains as one of the standard options in advanced CSCC management. Agents to improve response rates are needed and future trials should address the use of novel targeted and new chemotherapy combinations in CSCC.

(C) 2014 by Lippincott Williams & Wilkins, Inc

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/AJCOonline

For additional oncology content, visit LWW Oncology Journals on Facebook.